[1]
Buaboonnam, J. et al. 2021. LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING. Mediterranean Journal of Hematology and Infectious Diseases. 13, 1 (Oct. 2021), e2021065. DOI:https://doi.org/10.4084/MJHID.2021.065.